GeneDx Holdings (WGS) Notes Payables (2020 - 2023)

GeneDx Holdings (WGS) has reported Notes Payables for 4 consecutive years, with $4.3 million the latest figure, recorded in Q1 2023.

• On a quarterly basis, Notes Payables rose 33.3% year-over-year to $4.3 million in Q1 2023; TTM through Mar 2023 was $4.3 million, a 33.3% increase from a year earlier, with the FY2022 full-year figure at $3.6 million, up 36.98% from the prior year.
• Notes Payables was $4.3 million for Q1 2023 at GeneDx Holdings, up from $3.6 million in the prior quarter.
• Over five years, Notes Payables peaked at $4.3 million in Q1 2023 and troughed at $797000.0 in Q1 2021.
• A 4-year average of $2.3 million and a median of $2.1 million in 2022 frame the typical range for Notes Payables.
• The widest YoY moves for Notes Payables: up 306.15% in 2022, down 28.28% in 2022.
• Over 4 years, Notes Payables stood at $1.4 million in 2020, then jumped by 84.07% to $2.6 million in 2021, then jumped by 36.98% to $3.6 million in 2022, then gained by 20.09% to $4.3 million in 2023.
• The last three Notes Payables figures came in at $4.3 million (Q1 2023), $3.6 million (Q4 2022), and $1.8 million (Q3 2022), per Business Quant data.